Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

BH4 (tetrahydrobiopterin) strongly regulates this oxidation step as a cofactor, which is produced by guanosine triphosphate (GTP) by GTP cyclohydrolase (GPTCH). Then, aromatic amino acid decarboxylase ...